Abstract
Objective To investigate the clinical efficacy of Monostalotetrahexosylgangliside (GM1) in treatment of peripheral neuritis after chemotherapy.Methods 172 cases of peripheral neuritis after chemotherapy were randomly divided into two groups.Treatment group with 86 cases was treated with GM1,40 mg,intravenous infusion,one time a day,until the end of chemotherapy.Control group with 86 patients was treated with vitamin B6 tablets 60 mg,orally,three times a day,until the end of chemotherapy.Two groups were assessed respectively for efficacy.Results The effect of treatment group (80.2 ％) was obviously better than that of control group (8.1％).The difference was statistically significant (P＜0.05).Conclusions GM1 can relieve peripheral neuritis of breast cancer patients after chemotherapy. Key words: Monostalotetrahexosylgangliside; Peripheral neuritis; Chemotherapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
